Organovo’s FXR Program, including FXR314
The deal with Lilly is a crucial boost for Organovo, which ended last year with just $1.2 million in cash and nearly $350 million in debt. Organovo FXR is a clinical drug program focused on farnesoid ...
Organovo shares are trading higher by 246% Tuesday morning. The company announced that Eli Lilly is set to acquire its FXR ...
which includes Organovo's FXR program and its lead asset, FXR314, aimed at treating inflammatory bowel disease (IBD). Keith Murphy, Executive Chairman of Organovo, expressed excitement about the ...
Organovo today announced that Eli Lilly and Company (NYSE:LLY) ("Lilly") will acquire Organovo's FXR program, including its ...
3don MSN
Eli Lilly (NYSE: LLY) stock defied today's market downturn, rising 2.6% through 11:15 a.m. ET on the back of two positive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results